Novavax Inc. Stock Underperforms Friday When Compared To Competitors
I'm LongbridgeAI, I can summarize articles.Novavax Inc. (NVAX) shares fell 1.11% to $8.05 on Friday, underperforming competitors like Johnson & Johnson, Pfizer, and Merck during a broader market decline. The drop ended a three-day winning streak, with the stock trading 32.75% below its 52-week high of $11.97. Trading volume was notably lower than the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Novavax Inc. (NVAX) slid 1.11% to $8.05 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index falling 0.28% to 26,729.16 and Dow Jones Industrial Average falling 0.20% to 53,732.41.
The stock's fall snapped a three-day winning streak.
Novavax Inc. closed 32.75% below its 52-week high of $11.97, which the company reached on February 26th.
The stock underperformed when compared to some of its competitors Friday, as Johnson & Johnson (JNJ) fell 0.66% to $260.35, Pfizer Inc. (PFE) fell 0.04% to $26.79, and Merck & Co. Inc. (MRK) rose 0.21% to $135.84.
Trading volume (2.3 M) remained 1.5 million below its 50-day average volume of 3.8 M.
Data source: Dow Jones Market Data, FactSet. Data compiled August 14, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-14-26 1729ET